Two months later Fishman hired rheumatologist Wright, who proposed testing Novartis' own antibody in Muckle-Wells.

FORBES: Magazine Article

Research into these biologic antibody-based approaches is at an earlier stage than the testing of antagonist drugs, but antibodies eventually might be able to block CGRP action regularly so that migraines don't ever begin.

WSJ: Fresh Target in Hunt for a Migraine Cure